Do analysts prefer ANIX or TPST?

Anixa Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 254.17%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ANIX or TPST more profitable?

Anixa Biosciences' return on equity of -70.95% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -70.95% -62.53% Tempest Therapeutics N/A -355.61% -121.21%

Do analysts recommend AARD or TPST?

Aardvark Therapeutics currently has a consensus price target of $19.70, indicating a potential upside of 450.28%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aardvark Therapeutics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.46 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, AARD or TPST?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is AARD or TPST more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -61.71% -56.29% Tempest Therapeutics N/A -355.61% -121.21%

Does the media prefer AARD or TPST?

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 3 articles in the media. Tempest Therapeutics' average media sentiment score of 1.28 beat Aardvark Therapeutics' score of 0.37 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TPST or LONA?

Athira Pharma has a consensus target price of $15.00, suggesting a potential upside of 77.30%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable valuation and earnings, TPST or LONA?

Athira Pharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A Athira Pharma N/A N/A -$105.61M -$5.21 N/A

Is TPST or LONA more profitable?

Tempest Therapeutics' return on equity of -355.61% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Athira Pharma N/A -381.01% -225.74%

Does the media refer more to TPST or LONA?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Athira Pharma. Tempest Therapeutics' average media sentiment score of 1.28 beat Athira Pharma's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TPST or LIXT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, TPST or LIXT?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A

Is TPST or LIXT more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Lixte Biotechnology N/A -134.91% -95.61%

Does the media favor TPST or LIXT?

In the previous week, Lixte Biotechnology had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Lixte Biotechnology and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.28 beat Lixte Biotechnology's score of 0.22 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CUE or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer CUE or TPST?

In the previous week, Tempest Therapeutics had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Cue Biopharma. Tempest Therapeutics' average media sentiment score of 1.28 beat Cue Biopharma's score of 0.83 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tempest Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tempest Therapeutics (TPST) Competitors

$1.27 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.27 0.00 (0.00%)

As of 07:58 PM Eastern

Compare

TPST vs. ANIX, AARD, LONA, LIXT, and CUE

Should you buy Tempest Therapeutics stock or one of its competitors? MarketBeat compares Tempest Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tempest Therapeutics include Anixa Biosciences (ANIX), Aardvark Therapeutics (AARD), Athira Pharma (LONA), Lixte Biotechnology (LIXT), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry.

How does Tempest Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Anixa Biosciences. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.89 beat Tempest Therapeutics' score of 1.28 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Very Positive
Tempest Therapeutics	Positive

Anixa Biosciences has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, indicating that its stock price is 285% less volatile than the broader market.

Anixa Biosciences has higher revenue and earnings than Tempest Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	383.20	-$10.93M	-$0.33	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Anixa Biosciences' return on equity of -70.95% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
Tempest Therapeutics	N/A	-355.61%	-121.21%

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anixa Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 254.17%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Anixa Biosciences beats Tempest Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Tempest Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Aardvark Therapeutics has a beta of 4.47, suggesting that its share price is 347% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, suggesting that its share price is 285% less volatile than the broader market.

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 3 articles in the media. Tempest Therapeutics' average media sentiment score of 1.28 beat Aardvark Therapeutics' score of 0.37 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.5% of Tempest Therapeutics shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aardvark Therapeutics' return on equity of -61.71% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Aardvark Therapeutics currently has a consensus price target of $19.70, indicating a potential upside of 450.28%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aardvark Therapeutics is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Summary

Aardvark Therapeutics beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Athira Pharma?

Tempest Therapeutics (NASDAQ:TPST) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Tempest Therapeutics' return on equity of -355.61% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Athira Pharma	N/A	-381.01%	-225.74%

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 6.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 25.7% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Athira Pharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Tempest Therapeutics has a beta of -1.85, meaning that its share price is 285% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Athira Pharma. Tempest Therapeutics' average media sentiment score of 1.28 beat Athira Pharma's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma has a consensus target price of $15.00, suggesting a potential upside of 77.30%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Athira Pharma beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to Lixte Biotechnology?

Tempest Therapeutics (NASDAQ:TPST) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

In the previous week, Lixte Biotechnology had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Lixte Biotechnology and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.28 beat Lixte Biotechnology's score of 0.22 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lixte Biotechnology's return on equity of -134.91% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Tempest Therapeutics has a beta of -1.85, suggesting that its share price is 285% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Summary

Lixte Biotechnology beats Tempest Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Tempest Therapeutics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Cue Biopharma. Tempest Therapeutics' average media sentiment score of 1.28 beat Cue Biopharma's score of 0.83 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tempest Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tempest Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.65	-$26.60M	-$5.58	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Tempest Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Cue Biopharma has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Cue Biopharma beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TPST vs. The Competition

Export

Metric	Tempest Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.81M	$2.96B	$6.64B	$12.06B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	-0.21	12.37	20.93	22.06
Price / Sales	N/A	287.11	508.64	105.22
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	0.94	3.88	10.47	6.72
Net Income	-$26.26M	$75.85M	$3.56B	$337.35M
7 Day Performance	-3.05%	-1.46%	-1.11%	-2.54%
1 Month Performance	-36.18%	-5.33%	1.28%	1.42%
1 Year Performance	-85.81%	15.77%	21.20%	24.71%

Tempest Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TPST Tempest Therapeutics	2.7683 of 5 stars	$1.27 flat	N/A	-84.6%	$18.81M	N/A	N/A	20	Positive News Gap Down
ANIX Anixa Biosciences	2.0538 of 5 stars	$2.70 flat	$8.50 +214.8%	-10.9%	$90.53M	N/A	N/A	5	Positive News Upcoming Earnings
AARD Aardvark Therapeutics	3.8271 of 5 stars	$3.99 -2.9%	$19.70 +393.7%	-69.6%	$89.67M	N/A	N/A	18	Gap Down
LONA Athira Pharma	3.0074 of 5 stars	$9.29 -2.6%	$15.00 +61.5%	N/A	$89.61M	N/A	N/A	40
LIXT Lixte Biotechnology	0.4816 of 5 stars	$7.21 +15.4%	N/A	+400.1%	$89.28M	N/A	N/A	4	Short Interest Increase Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tempest Therapeutics (TPST) Competitors

TPST vs. ANIX, AARD, LONA, LIXT, and CUE

How does Tempest Therapeutics compare to Anixa Biosciences?

Summary

How does Tempest Therapeutics compare to Aardvark Therapeutics?

Summary

How does Tempest Therapeutics compare to Athira Pharma?

Summary

How does Tempest Therapeutics compare to Lixte Biotechnology?

Summary

How does Tempest Therapeutics compare to Cue Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tempest Therapeutics (TPST) Competitors

TPST vs. ANIX, AARD, LONA, LIXT, and CUE

How does Tempest Therapeutics compare to Anixa Biosciences?

Does the media prefer ANIX or TPST?

Which has more risk & volatility, ANIX or TPST?

Which has preferable valuation and earnings, ANIX or TPST?

Is ANIX or TPST more profitable?

Do insiders and institutionals believe in ANIX or TPST?

Do analysts prefer ANIX or TPST?

Summary

How does Tempest Therapeutics compare to Aardvark Therapeutics?

Which has more risk & volatility, AARD or TPST?

Does the media prefer AARD or TPST?

Do institutionals & insiders believe in AARD or TPST?

Is AARD or TPST more profitable?

Do analysts recommend AARD or TPST?

Which has stronger earnings and valuation, AARD or TPST?

Summary

How does Tempest Therapeutics compare to Athira Pharma?

Is TPST or LONA more profitable?

Do institutionals and insiders hold more shares of TPST or LONA?

Which has preferable valuation and earnings, TPST or LONA?

Which has more volatility & risk, TPST or LONA?

Does the media refer more to TPST or LONA?

Do analysts recommend TPST or LONA?

Summary

How does Tempest Therapeutics compare to Lixte Biotechnology?

Do analysts recommend TPST or LIXT?

Which has higher valuation and earnings, TPST or LIXT?

Does the media favor TPST or LIXT?

Do institutionals & insiders have more ownership in TPST or LIXT?

Is TPST or LIXT more profitable?

Which has more volatility and risk, TPST or LIXT?

Summary

How does Tempest Therapeutics compare to Cue Biopharma?

Does the media prefer CUE or TPST?

Do insiders and institutionals believe in CUE or TPST?

Which has preferable earnings & valuation, CUE or TPST?

Is CUE or TPST more profitable?

Which has more volatility and risk, CUE or TPST?

Do analysts rate CUE or TPST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TPST vs. The Competition

Tempest Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools